StockNews.com Begins Coverage on Sorrento Therapeutics (NASDAQ:SRNE)

Stock analysts at StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

SRNE opened at $0.02 on Tuesday. The stock’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.05. Sorrento Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.42.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.